Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; Department of Emergency and Transport Medicine, National Center for Child Health and Development, Tokyo, Japan.
Department of Emergency and Transport Medicine, National Center for Child Health and Development, Tokyo, Japan.
World Neurosurg. 2024 Oct;190:481-486.e2. doi: 10.1016/j.wneu.2024.08.057. Epub 2024 Aug 13.
Intracranial pressure (ICP) monitoring and monitoring of brain tissue oxygen (Pbto2) in addition to ICP have been used in the management of traumatic brain injury (TBI). However, the optimal monitoring method is inconclusive. We searched 4 databases with no language restrictions through January 2024 for peer-reviewed randomized controlled trials (RCTs) comparing ICP monitoring with combined Pbto2 and ICP monitoring in patients with traumatic brain injury. A favorable neurologic outcome was the primary outcome, and the secondary outcome was survival. Two reviewers screened manuscripts, extracted data, and assessed the risk of bias. We then performed a meta-analysis to assess efficacy using the Grading of Recommendations, Assessment, Development, and Evaluation working group approach. We included 5 trials comprising 512 patients. There was no difference in favorable neurologic outcome (risk ratio: 1.21; 95% confidence interval: 0.93, 1.58; I2: 45%; 5 RCTs: 512 patients; moderate certainty) and survival (risk ratio: 1.10; 95% confidence interval: 0.99, 1.21; I2: 13%; 5 RCTs: 512 patients; moderate certainty). We found no evidence that the combination of Pbto2 and ICP is more useful than ICP. The included RCTs are few and small, and further study is needed to draw conclusions.
颅内压 (ICP) 监测和脑氧监测 (Pbto2) 除了 ICP 监测之外,还用于创伤性脑损伤 (TBI) 的管理。然而,最佳监测方法尚无定论。我们对四个数据库进行了无语言限制的搜索,截至 2024 年 1 月,以寻找比较 ICP 监测与联合 Pbto2 和 ICP 监测在创伤性脑损伤患者中的随机对照试验 (RCT)。神经功能结局良好是主要结局,次要结局是生存。两名评审员筛选文献、提取数据并评估偏倚风险。然后,我们使用推荐评估、制定与评估工作组方法进行荟萃分析,评估疗效。我们纳入了 5 项试验,共 512 名患者。神经功能结局良好(风险比:1.21;95%置信区间:0.93,1.58;I2:45%;5 项 RCT:512 名患者;中等确定性)和生存(风险比:1.10;95%置信区间:0.99,1.21;I2:13%;5 项 RCT:512 名患者;中等确定性)无差异。我们没有证据表明 Pbto2 和 ICP 的联合使用比 ICP 更有用。纳入的 RCT 数量少且规模小,需要进一步研究才能得出结论。